The inhibitory effects of fluoroquinolones on l-carnitine transport in placental cell line BeWo

International Journal of Pharmaceutics

Volumn 351, Issue 1-2, 2008, Pages 113-118

  Hirano, Takeshi ^a   Yasuda, Satoru ^a   Osaka, Yuki ^a   Asari, Masaru ^a   Kobayashi, Masaki ^a   Itagaki, Shirou ^a   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

BeWo; Fluoroquinolone; l Carnitine; Levofloxacin

Indexed keywords

AMPHOLYTE; CARNITINE; CIPROFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; ORGANIC CATION TRANSPORTER 2; SODIUM ION;

AMINO ACID TRANSPORT; ARTICLE; DRUG INTERACTION; DRUG NUTRIENT INTERACTION; HUMAN; HUMAN CELL; PLACENTA; PRIORITY JOURNAL;

BIOLOGICAL TRANSPORT; CARNITINE; CELL LINE, TUMOR; CIPROFLOXACIN; DRUG INTERACTIONS; FLUOROQUINOLONES; HUMANS; OFLOXACIN; ORGANIC CATION TRANSPORT PROTEINS; PIPERAZINES; PLACENTA; SODIUM;

EID: 38749110047     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.022     Document Type: Article

References (35)

1. Bremer J. Carnitine-metabolism and functions. Physiol. Rev. 63 (1983) 1420-1480
2. Brownell A.K., Severson D.L., Thompson C.D., and Fletcher T. Cold induced rhabdomyolysis in carnitine palmyityl transferase deficiency. Can. J. Neurol. Sci. 6 (1979) 367-370
3. Ganphaichitr V., and Leelahagul P. Carnitine metabolism and human carnitine deficiency. Nutrition 9 (1993) 246-254
4. Gonzalez-Alvarez I., Fernandez-Teruel C., Garrigues T.M., Casabo V.G., Ruiz-Garcia A., and Bermejo M. Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica 35 (2005) 1067-1088
5. Grube M., Schwabedissen H.M., Draber K., Prager D., Moritz K.U., Linnemann K., Fusch C., Jedlitschky G., and Kroemer H.K. Expression, localization, and function of the carnitine transporter OCTN2 (slc22a5) in human placenta. Drug Metab. Dispos. 33 (2005) 31-37
6. Hirano T., Iseki K., Miyazaki S., Takada M., Kobayashi M., Sugawara M., and Miyazaki K. The stimulative effect of diffusion potential on enoxacin uptake across rat intestinal brush-border membranes. J. Pharm. Pharmacol. 46 (1994) 676-679
7. Hirano T., Iseki K., Sato I., Miyazaki S., Takada M., Kobayashi M., Sugawara M., and Miyazaki K. The intestinal transport mechanism of fluoroquinolones: inhibitory effect of ciprofloxacin, an enoxacin derivative, on the membrane potential-dependent uptake of enoxacin. Pharm. Res. 12 (1995) 1299-1303
8. Hirano T., Yasuda S., Osaka Y., Kobayashi M., Itagaki S., and Iseki K. Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. Biochim. Biophys. Acta 1758 (2006) 1743-1750
9. Holme E., Greter J., Jacobson C.E., Lindstedt S., Nordin I., Kristiansson B., and Jodal U. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 2 (1989) 469-473
10. Hug G., McGraw C.A., Bates S.R., and Landrigan E.A. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J. Pediatr. 119 (1991) 799-802
11. Igarashi N., Sato T., and Kyouya S. Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet. Acta Paediatr. Jpn. 32 (1990) 139-145
12. Itoh T., Itagaki S., Sumi Y., Hirano T., Takemoto I., and Iseki K. Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2. Cancer Chemother. Pharmacol. 55 (2005) 420-424
13. Kuntzer T., Reichmann H., Bogousslavsky J., and Regli F. Emetine-induced myopathy and carnitine deficiency. J. Neurol. 237 (1990) 495-496
14. Lahjouji K., Elimrani I., Lafond J., Leduc L., Qureshi I.A., and Mitchell G.A. l-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am. J. Physiol. Cell Physiol. 287 (2004) C263-C269
15. Lahjouji K., Malo C., Mitchell G.A., and Qureshi I.A. l-Carnitine transport in mouse renal and intestinal brush-border and basolateral membrane vesicles. Biochim. Biophys. Acta 1558 (2002) 82-93
16. Matsuo Y., Yano I., Ito T., Hashimoto Y., and Inui K. Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1. J. Pharmacol. Exp. Ther. 287 (1998) 672-678
17. Morinaga T., Fujii S., Furukawa S., Kikumori M., Yasuhira K., Shindo Y., Watanabe M., and Sumi N. Reproductive and developmental toxicity studies of prulīoxacin (NM441)(2)-a teratogenicity study in rats by oral administration. J. Toxicol. Sci. 21 (1996) 187-206
18. Ohashi R., Tamai I., Nezu J., Nikaido H., Hashimoto N., Oku A., Sai Y., Shimane M., and Tsuji A. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol. 59 (2001) 358-366
19. Petitjeans F., Nadaud J., Perez J.P., Debien B., Olive F., Villevieille T., and Pats B. A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin. Eur. J. Clin. Pharmacol. 59 (2003) 779-780
20. Polachek H., Holcberg G., Sapir G., Tsadkin-Tamir M., Polachek J., Katz M., and Ben-Zvi Z. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol. 122 (2005) 61-65
21. Pons R., and De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J. Child Neurol. 10 (1995) S8-S24
22. Rytting E., and Audus K.L. Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J. Pharmacol. Exp. Ther. 312 (2005) 192-198
23. Sasabe H., Kato Y., Suzuki T., Itose M., Miyamoto G., and Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J. Pharmacol. Exp. Ther. 310 (2004) 648-655
24. Scholte H.R., Pereira R.R., de Jonge P.C., Luyt-Houwen I.E.M., Hedwig M., Verduin M., and Ross J.D. Primary carnitine deficiency. J. Clin. Chem. Clin. Biochem. 28 (1990) 351-357
25. Shekhawat P., Bennett M.J., Sadovsky Y., Nelson D.M., Rakheja D., and Strauss A.W. Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E1098-E1105
26. Tamai I., Ohashi R., Nezu J., Yabuuchi H., Oku A., Shimane M., Sai Y., and Tsuji A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 273 (1998) 20378-20382
27. Tamai I., Yabuuchi H., Nezu J., Sai Y., Oku A., Shimane M., and Tsuji A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 419 (1997) 107-111
28. Treem T.R., Stanley C.A., Finegold D.N., Hale D.E., and Coates P.M. Primary carnitine deficiency due to failure of carnitine transport in kidney, muscle, and fibroblasts. N. Engl. J. Med. 319 (1988) 1331-1336
29. Tune B.M., and Hsu C.Y. Toxicity of cephaloridine to carnitine transport and fatty acid metabolism in rabbit renal cortical mitochondria: structure-activity relationships. J. Pharmacol. Exp. Ther. 270 (1994) 873-878
30. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58 (1999) 29-36
31. Watanabe T., Fujikawa K., Harada S., Ohura K., Sasaki T., and Takayama S. Reproductive toxicity study of new quinolones antibacterial agent levofloxacin in rats and rabbits. Arzneim. Forsch. 43 (1992) 374-377
32. Wu S.P., Shyu M.K., Liou H.H., Gau C.S., and Lin C.J. Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 45 (2004) 204-210
33. Yamaguchi H., Yano I., Hashimoto Y., and Inui K. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. J. Pharmacol. Exp. Ther. 295 (2000) 360-366
34. Yamaguchi H., Yano I., Saito H., and Inui K. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur. J. Pharmacol. 431 (2001) 297-303
35. Young A.M., Allen C.E., and Audus K.L. Efflux transporters of the human placenta. Adv. Drug Deliv. Rev. 55 (2003) 125-132